High levels of C-reactive protein (CRP), a protein that is produced in response to inflammation, contribute to heart tissue damage that accompanies heart attack and stroke.

Recent research: A new drug called bis-(phosphocholine)-hexane has been shown in laboratory studies to block CRP's tissue-damaging effects. The drug is the first to selectively inhibit CRP.

Next: Clinical trials on bis(phosphocholine)-hexane are expected to begin within the next two years.

Want to Keep Reading?

Continue reading with a Health Confidential membership.

Sign up now Already have an account? Sign in